Post-marketing surveillance of AVIGAN tablets 200mg (SFTS)
Recruiting
- Conditions
- Severe Fever with Thrombocytopenia Syndrome
- Registration Number
- jRCT2031240539
- Lead Sponsor
- FUJIFILM Toyama Chemical Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 340
Inclusion Criteria
All patients treated with AVIGAN tablets 200 mg
Exclusion Criteria
none
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method - Incidence of adverse drug reactions
Incidence of serious adverse events
- Secondary Outcome Measures
Name Time Method Mortality rate (by patient demographics and disease characteristics) at the time of discontinuation of AVIGAN tablets 200 mg or discharge (including death), cumulative mortality rate up to Day 28 after the start of administration Mortality rate categorized by patient demographics and disease characteristics